Clinical Trials Browser

Interventional × Waldenstrom Macroglobulinemia × zanubrutinib × Clear all

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07474961 2026-03-16

BLOOD-dose

Phase 4 Not yet recruiting

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT04463953 2026-02-11

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Phase 2 Completed

Waldenstrom Macroglobulinemia

NCT04116437 2026-01-28

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Phase 2 Completed

LymphoidOther hematologic neoplasm

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05952037 2026-01-02

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

Phase 2 Active not recruiting

Lymphoma, Waldenstrom Macroglobulinemia

NCT07169331 2025-12-19

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

Phase 4 Recruiting

Waldenstrom Macroglobulinemia

NCT06547866 2025-11-26

WAZABI

Phase 2 Not yet recruiting

Waldenstrom Macroglobulinemia

NCT06561347 2025-11-24

ZEBRA

Phase 2 Recruiting

Waldenstrom Macroglobulinemia

NCT04172246 2025-11-21

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Phase 1/2 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06942507 2025-04-30

BRZ-WM

Phase NA Not yet recruiting

Waldenstrom Macroglobulinemia

NCT03053440 2024-10-26

ASPEN

Phase 3 Completed

201 enrolled 19 charts 1 FDA

Waldenstrom Macroglobulinemia

NCT03332173 2024-10-26

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Phase 2 Completed

44 enrolled 13 charts

Waldenstrom Macroglobulinemia

NCT05914662 2024-08-28

ZBR

Phase 2 Recruiting

Waldenstrom Macroglobulinemia

NCT05979948 2023-09-14

CZ-WM01

Phase 2 Unknown

Waldenstrom Macroglobulinemia